World Investment Advisors Has $5.08 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

World Investment Advisors lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,548 shares of the medical research company’s stock after selling 3,729 shares during the quarter. World Investment Advisors’ holdings in Edwards Lifesciences were worth $5,075,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of EW. Townsquare Capital LLC increased its holdings in shares of Edwards Lifesciences by 20.5% during the 3rd quarter. Townsquare Capital LLC now owns 5,208 shares of the medical research company’s stock worth $344,000 after acquiring an additional 886 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of Edwards Lifesciences by 12.5% in the third quarter. Public Sector Pension Investment Board now owns 26,167 shares of the medical research company’s stock valued at $1,727,000 after purchasing an additional 2,900 shares during the last quarter. Edgestream Partners L.P. raised its position in shares of Edwards Lifesciences by 117.1% in the third quarter. Edgestream Partners L.P. now owns 10,294 shares of the medical research company’s stock valued at $679,000 after purchasing an additional 5,552 shares during the period. Benjamin Edwards Inc. lifted its stake in shares of Edwards Lifesciences by 6,929.4% during the 3rd quarter. Benjamin Edwards Inc. now owns 15,324 shares of the medical research company’s stock worth $1,011,000 after buying an additional 15,106 shares during the last quarter. Finally, Centiva Capital LP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $295,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $73.03 on Friday. The business has a fifty day simple moving average of $71.73 and a 200 day simple moving average of $70.62. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $42.93 billion, a P/E ratio of 10.48, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.